

Amendments

Please amend the claims to read, as follows:

37. **(Three Times Amended)** A pharmaceutical kit comprising:

(a) a first component comprising a bifunctional fusion glycoprotein or conjugate thereof comprising

(i) at least one first portion which is an enzyme selected from the group consisting of penicillin G amidase, penicillin V amidase, β -lactamase, alkaline phosphatase, carboxypeptidase G2, carboxypeptidase A, cytosine deaminase, nitroreductase, diaphorase, arylsulfatase, glycosidase, β -glucosidase, and β -glucuronidase; and

(ii) at least one second portion which comprises a monoclonal antibody BW 431/26 or an antigen binding fragment thereof that binds said first component to a tumor-specific antigen on a tumor cell;

wherein said fusion glycoprotein or conjugate thereof comprises at least one exposed carbohydrate residue selected from the group consisting of mannose, galactose, N-acetylglucosamine, lactose, N-acetyllactose, glucose and fucose; and

(b) a second component comprising a non-toxic prodrug that is subsequently cleaved into a tumor cytotoxic drug by said enzymatic activity of said first component,

wherein each of said first and said second components is in a pharmaceutically acceptable vehicle.

58. **(Three Times Amended)** A method of treating a tumor in a subject, comprising:

(a) administering to said subject in a first step, a first component comprising a bifunctional fusion glycoprotein or conjugate thereof comprising

(i) at least one first portion which is an enzyme selected from the group consisting of penicillin G amidase, penicillin V amidase, β -lactamase, alkaline phosphatase, carboxypeptidase G2, carboxypeptidase A, cytosine deaminase, nitroreductase, diaphorase, arylsulfatase, glycosidase, β -glucosidase, and β -glucuronidase; and

(ii) at least one second portion which comprises a monoclonal antibody BW 431/26 or an antigen binding fragment thereof that binds said first component to a tumor-specific antigen on a tumor cell;

wherein said fusion glycoprotein or conjugate thereof comprises at least one exposed carbohydrate residue selected from the group consisting of mannose, galactose, N-acetylglucosamine, lactose, N-acetylglucose, glucose and fucose; and

(b) administering to said subject in a second step, a second component comprising a non-toxic prodrug that is subsequently cleaved into a tumor cytotoxic drug by said enzymatic activity of said first component,

wherein each of said first and said second components is in a pharmaceutically acceptable vehicle.

66. **(Amended)** A pharmaceutical kit comprising:

(a) a first component comprising a bifunctional fusion glycoprotein or conjugate thereof of the formula huTuMab-L- β -Gluc, wherein huTuMab is a human tumor specific monoclonal antibody or an antigen binding fragment thereof, L is said linker molecule, and β -Gluc is a human β -glucuronidase;

wherein said glycoprotein or conjugate thereof comprises at least one exposed carbohydrate residue selected from the group consisting of mannose, galactose, N-acetylglucosamine, lactose, N-acetyllactose, glucose and fucose; and

F3 (b) a second component comprising a non-toxic prodrug that is subsequently cleaved into a tumor cytotoxic drug by said enzymatic activity of said first component.

67. (Amended) A method of treating a tumor in a subject, comprising:

nk (a) administering to said subject in a first step, a first component comprising a first component comprising a bifunctional fusion glycoprotein or conjugate thereof of the formula huTuMab-L- β -Gluc, wherein huTuMab is a human tumor specific monoclonal antibody or an antigen binding fragment thereof, L is said linker molecule, and β -Gluc is a human β -glucuronidase;

wherein said glycoprotein or conjugate thereof comprises at least one exposed carbohydrate residue selected from the group consisting of mannose, galactose, N-acetylglucosamine, lactose, N-acetyllactose, glucose and fucose; and

(b) administering to said subject in a second step, a second component comprising a non-toxic prodrug that is subsequently cleaved into a tumor cytotoxic drug by said enzymatic activity of said first component.